Levetiracetam: an open label study on safety and efficacy in newly diagnosed partial onset seizures as monotherapy
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20161900Keywords:
Levetiracetam (LEV), Children’s, Epilepsy, Partial seizureAbstract
Background: The Common neurological disorder in pediatric population is epilepsy. Despite having many medications and with recent approval of levetiracetam (LEV) as an adjunctive treatment in children, there is a need to evaluate safety and efficacy of this drug in Indian population. The aim was to study the efficacy and tolerability of levetiracetam as monotherapy, in newly diagnosed partial onset seizures.
Methods: Newly diagnosed partial seizure patients attending the neurology outpatient department were considered for the study based on the inclusion criteria. After the patients were started on the minimal therapeutic dose of the allocated drug LEV 500 mg twice daily over a period of 2 weeks, if there is no adequate seizure control, the dose of medication was further stepped up. Dose level 2 was taken as 1000 mg twice daily for levetiracetam over next 2 weeks. Dose level 3, 1500 mg twice daily for levetiracetam for the final 2 weeks (Maximum dose tried). After 6 weeks of dose stabilization, all patients had a final evaluation at the end of 6 months to assess for 6 month seizure free period.
Results: Out of 37 subjects who had first visit eligibility on screening 5 did not give consent 2 were in exclusion criteria with 30 involved in study three were lost in follow up. Among 28 children in levetiracetam group 17 (62.96%) had seizure control at 6 months with dose level 1 (20 mg/kg/day) itself. 8 patients (25.92%) had control on dose level 2 (30 mg/kg/day). 2 patients (7.40%) had seizure control at maximum dose level 3 (40 mg/kg/day). In 1 patient, seizures were not controlled in spite of maximum dose. This patient was started on alternative drugs. The commonest discomfort faced by the subjects include nausea 14 (51.85 %), drowsiness 11 (40.74%), unsteadiness 6 (27%), diplopia 6 (20%) and headache 6 (20%).
Conclusions: Though the present study is an analysis of small population and open labeled, the results are clear levetiracetam as monotherapy is effective in majority of study population at a dose of 20 to 40 mg/kg/day. The cost effectiveness and safety of the drug has also given promising results for its usage among pediatric age group. A study on large group with comparison to existing gold standard drugs with proven efficacy in children like gabapentin, topiramate, oxcarbazepine and lamotrigine can give more information as monotherapy and its use as adjunctive drug.
References
Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol. 2002;17(1):4-17.
CDC. targeting epilepsy: improving the lives of people with one of the nation’s most common neurological conditions. 2011. Available from: http://www.cdc.gov/chronicdisease/resources/publications/AAG/epilepsy.htm. Accessed on 23 January 2013.
French JA, Kanner AM, Bautista J. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society. Neurology. 2004;62(8):1261-73.
Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia. 1997;38(9):21-31.
Chadwick DW. Monotherapy clinical trials of new antiepileptic drugs: design, indication and controversies. Epilepsia. 1997;38(9):16-20.
Garza JE, Nordli DR, Rating D. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009;50(5):1141-9.
Perry MS, Benatar M. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Epilepsia. 2007;48(6):1123-7.
Pellock JM. Drug treatment in children. In: Engel J, Pedley TA eds. Epilepsy: a comprehensive textbook. Philadelphia:Lippincott-Raven;1997:1205-10.
Berger MI. Economic analysis of health care technology; A report on principles. Ann Intern Med. 1995;122;61-70.
Cereghino JJ, Biton V, Abou-khalil B. Levetiracetam for partial seizures: results of a double blind, randomized clinical trial. Neurology. 2000;55:236-42.
Shorvon SD, Janz D, Lowenthal A. Multicenter double blind randomized, placebo-controlled trial of levetiracetam as add-on therapy in patient with refractory partial seizures. Epilepsy. 2000;41:1179-86.
Ben ME, Falter U. Efficacy and tolerability of Levetiracetam 3000 mg/day in patient with refractory partial onset seizures: a multicenter, double blind, responder-selected study evaluating monotherapy. Epilepsia. 2000;41:1276-83.
Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the lennox-gastaut syndrome). Epilepsia. 1997;38:68-73.
Elterman RD, Glauser TA, Wylie E. A double blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology. 1999;52:13338-44.
